The US Preventive Services Task Force (USPSTF) endorses routine screening for genetic risk of breast and/or ovarian cancer as a component of primary health care. Implementation of this recommendation may prove challenging, especially in clinics serving disadvantaged communities. METHODS: The authors tested the feasibility of implementing the USPSTF mandate at a federally qualified health center (FQHC) to identify women who were eligible for genetic counseling (GC). A 12-month usual-care phase was followed by a 12-month intervention phase, during which time cancer genetic risk assessment (CGRA) was systematically performed for all women aged 25 to 69 years who presented for an annual examination. Women who were eligible for GC were recruited to participate in the study. RESULTS: After initiating CGRA, 112 women who were eligible for GC consented to study participation, and 56% of them received a referral for GC from their primary care physician. A subgroup of 50 participants were seen by the same primary care physician during both the usual-care and intervention phases. None of these patients was referred for GC during usual care, compared with 64% after the initiation of CGRA (P < .001). Only 16% of referred participants attended a GC session. CONCLUSIONS: Implementing USPSTF recommendations for CGRA as a standard component of primary health care in FQHCs is feasible and improves referral of minority women for GC, but more work is needed to understand the beliefs and barriers that prevent many underserved women from accessing cancer genetic services.
INTRODUCTION
Advances in cancer genetics and risk assessment make it possible to identify women who are at increased risk of developing breast and ovarian cancer. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Risk prediction through DNA testing of BRCA1/2 1,2 and other genes predisposing to breast cancer 9 and risk estimation with empiric models [3] [4] [5] [6] [7] [8] in families without a detectable mutation now are routinely recommended for women with a family history indicating a high risk of a genetic predisposition toward breast and ovarian cancer. [11] [12] [13] [14] Identifying asymptomatic women with genetic risk provides an opportunity to offer enhanced screening and preventive measures. [13] [14] [15] [16] [17] [18] [19] The population health benefits that could result from enhanced cancer screening and prevention strategies targeted to women at increased risk [13] [14] [15] [16] [17] [18] will be realized only if primary care physicians (PCPs) routinely assess for genetic risk. A recent update of the US Preventive Services Task Force (USPSTF) statement on genetic risk assessment for breast cancer recommended that PCPs routinely screen all women reporting a family history of breast or ovarian cancer with validated tools so that those at risk of hereditary breast cancer are referred for genetic counseling (GC). 11 Available evidence has indicated that PCPs are not routinely incorporating cancer genetic risk assessment (CGRA) into their practices. [20] [21] [22] [23] [24] [25] African American women are even less likely than non-Hispanic white women to undergo GC and DNA testing for breast cancer susceptibility. [26] [27] [28] [29] [30] Implementing the USPSTF mandate for the systematic assessment of genetic risk of breast and/or ovarian cancer in community health clinics provides an opportunity to impact the high rate of breast cancer mortality affecting underserved African American communities 31 by identifying asymptomatic women at increased risk who will benefit
Cancer September 15, 2018 from referral for GC and enhanced cancer control measures. 11 Herein, we report a feasibility study that examined implementation of the USPSTF recommendation for universal CGRA in a federally qualified health center (FQHC) as a novel strategy to address the high rate of breast cancer mortality among African American women in the United States. 31 
MATERIALS AND METHODS

Study Design
We conducted a single-arm study testing the feasibility of incorporating systematic CGRA as a standard component of routine well care at 2 clinic sites belonging to an FQHC in Chicago, Illinois. A "usual-care phase" lasting 12 months began in October 2012 after a mandatory 1.5-hour education session for all PCPs at the participating FQHC. Providers were educated regarding CGRA and the guideline-based management of women with an increased risk of breast cancer, including indications for GC referral. Providers were informed that they could refer their patients to a collaborating high-risk clinic for GC at no cost to the patient through a federal research grant. A second mandatory 1.5-hour all-provider refresher session was conducted at the conclusion of the usual-care phase. At that time, PCPs were informed that CGRA would be performed for all of their adult female patients presenting for an annual visit, and that they would receive clinical decision support along with the CGRA results. An "intervention phase" lasting 12 months began in November 2013 after the second provider meeting. During the intervention phase, CGRA was performed by research staff as part of the clinics' check-in process for all women aged 25 to 69 years who had no personal history of breast cancer and were presenting for an annual examination or new patient visit ("universal CGRA"). The PCP received a hard copy of the CGRA result and clinical decision support that included a recommendation for GC referral for all women eligible for GC based on national practice guidelines. 11, 14 Women learned the results of their assessment and the recommended care directly from their physician during the clinic visit. All women who met guideline-based criteria for GC referral were invited to participate in the study. Figure 1 shows the selection of study participants. The study protocol was approved by the institutional review board at the University of Illinois at Chicago.
Risk assessment instrument
CGRA was performed on tablet computers with a Webbased software application developed by study investigators. The software collects family cancer history information and uses the Pedigree Assessment Tool (PAT) 32, 33 and criteria from version 1.2011 of the National Comprehensive Cancer Network (NCCN) guidelines for DNA testing for the hereditary breast and ovarian cancer syndrome (HBOC) 14 to identify appropriate candidates for GC referral. The PAT is a point scoring system (see Supporting Table 1 ) weighted to account for high-risk family features that assigns points for each case of breast and ovarian cancer in both parental lineages. The PAT identifies individuals at high risk of HBOC according to criteria widely accepted at the time the PAT was developed in 2006 (≥10% pretest probability of detecting a BRCA mutation). The PAT was validated in 2 independent data sets, 32, 33 and has been endorsed by the USPSTF as a validated tool for screening women in primary care to identify candidates for GC due to a highrisk family history of breast and/or ovarian cancer. 11 Recent NCCN guidelines for DNA testing for HBOC include all family history scenarios that generate a PAT score above the threshold for GC referral, but the guidelines also now include family history scenarios that result in a PAT score below the referral threshold (eg, a single case of ovarian cancer at any age, a single case of breast cancer diagnosed at age ≤45 years, or a single case of triple-negative breast cancer diagnosed at age ≤60 years).
14 Therefore, the CGRA software supplements the PAT score with NCCN criteria (version 1.2011) (see Supporting Table 2 ) to identify women who are eligible for GC referral. The PCP received a hard copy of the CGRA result and clinical decision support that recommended GC referral for women eligible for counseling based on national practice guidelines.
11,14
Recruitment of study participants
Women were recruited to participate during the intervention phase of the study immediately after CGRA was completed (before learning the result of the assessment). Women were invited to participate if: 1) the CGRA tool identified them as being eligible for GC referral; and 2) they were not pregnant or lactating at the time of study enrollment. Participants provided consent for medical record review, completed an enrollment survey before learning results of the CGRA, and completed a brief exit survey immediately after the appointment with their PCP. Participants received a $10 incentive at the time of study enrollment.
Measures
The primary outcomes were the rate of successful completion of CGRA before the PCP encounter for all women eligible for CGRA, and the rate of PCP adherence to guideline-based criteria for GC referral within 6 months of CGRA for women who were eligible for GC Cancer September 15, 2018 and who consented to study participation (in preliminary work [unpublished data], nearly all women who eventually attended a GC session had done so within 6 months of referral). Secondary outcomes included improvements in the rate of GC referral for the subgroup of study participants who saw the same PCP during the usual-care and intervention phases, and the rate of patient compliance with referral recommendation and other cancer control measures (not included in the current study). Exploratory outcomes included associations between provider and patient characteristics and the primary and secondary outcomes. Adherence to guideline-based criteria for GC referral and attendance at a GC consultation for referred women was determined from chart reviews.
Provider and patient demographic characteristics used in exploratory analyses were self-reported though a survey administered at the beginning of the intervention phase (providers) or at the time of study enrollment (patients). Demographic data were not collected for women who underwent CGRA but were not enrolled in the study.
Statistical Analysis
The McNemar test compared the rate of GC referral before versus after the initiation of universal CGRA. Pearson chi-square tests were used for exploratory analyses to examine associations between categorical independent variables and dependent variables. Fisher exact tests were used for cell sizes <5. Analyses were conducted Cancer September 15, 2018 using Stata statistical software (version 13; StataCorp LLC, College Station, Texas).
RESULTS
Feasibility of Implementing Universal CGRA
During the intervention phase, all 1269 women who were eligible for CGRA (100%) completed the assessment before their encounter with their PCP. This was accomplished without disrupting physician workflow because the study protocol required termination of the assessment as soon as the patient was called to the examination room. The mean time to complete the assessment was 3.3 minutes for women at increased risk (standard deviation, 1.11) and 2.2 minutes for women at average risk (standard deviation, 1.10). These findings indicate that it is feasible to implement universal CGRA in a primary care context using a technology-enabled approach with minimal additional staff time, and without impeding patient flow.
Characteristics of the Study Participants
Of the 1269 women completing CGRA, 149 met established criteria for GC referral (11.7%); 148 of these women were invited to participate in the study and 112 (76% of the invited participants) consented to study participation (Fig. 1) . Data regarding these 112 women is reported herein. Supporting Table 3 demonstrates baseline characteristics of the 112 high-risk study participants, which consisted nearly entirely of economically disadvantaged racial/ethnic minority women (69% African American and 29% Latina, with 86% reporting an annual household income <$30,000).
Referral for GC
A referral for GC was initiated by the PCP within 6 months of study enrollment for 63 of the 112 study participants (56%) (Fig. 2a) . Preplanned subgroup analysis among the 50 participants who had an annual visit with the same PCP during both the usual-care phase and the intervention phase demonstrated that the referral rate increased from 0% during usual care to 64% (32 of 50 referred participants) after the initiation of universal CGRA (P < .001) (Fig. 2b) .
There was wide variability among PCPs with regard to the rate of adherence to guideline-based recommendations for GC referral (see Supporting Fig. 1 ). The design of this feasibility study (ie, total of only 14 providers and 112 participants who were eligible for GC referral) limited our ability to identify provider and patient characteristics associated with referral, and all associations reported (Table 1) should be viewed as exploratory. However, some trends did emerge. Family medicine/internal medicine physicians were more likely to refer patients to GC than obstetrician/gynecologists (66% vs 48%; P = .06), and providers with fewer years in practice also referred at a higher rate (66% vs 44%; P = .02). It should be noted that the latter result appears to be due to a single outlier PCP who had the highest number of patients eligible for GC and the lowest referral rate. Therefore, this finding cannot Rate of referral for genetic counseling for the subgroup of participants who were seen by the same primary care physician (PCP) during the usual-care phase and during the intervention phase (after the initiation of universal CGRA). The difference in the rate of referral was found to be statistically significant at P = .001 using the McNemar test.
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Cancer September 15, 2018 be generalized from our data. Trends also were noted for higher referral rates among women with private insurance and those with an annual household income >$30,000, but these differences were not statistically significant due to the small number of women in those categories. Beyond that, patient demographic characteristics did not predict referral for GC in this feasibility study with a small sample size and with limited variability in demographic characteristics among study participants.
Attendance at a GC Session
Of the 63 women who were referred for GC by their PCP, 21 scheduled an appointment for a GC session (19% of women who were eligible for GC; 33% of referred women), but only 10 participants attended the appointment (9% of eligible women; 16% of referred women) (Fig. 2a) . In exploratory analyses (Table 2) , having a nonAfrican American PCP and having a residential address that was a greater distance from the high-risk clinic were associated with attending the GC appointment. There Cancer September 15, 2018 also was a trend toward higher attendance noted among non-African American participants (29% vs 8%; P = .06).
DISCUSSION
To the best of our knowledge, this is the first prospective study to test the feasibility of implementing the USPSTF mandate that PCPs systematically screen for genetic risk of breast and/or ovarian cancer with GC referral as the outcome. We found that implementing the USPSTF recommendation is feasible in the FQHC setting using a technology-enabled approach, with 100% of women completing the assessment while they waited to see the provider. The strategy tested was very effective at improving referrals for GC among high-risk women (0% at baseline vs 64% after the intervention for the subgroup of participants who were seen both before and after the initiation of universal CGRA). The 56% overall rate of guideline-concordant referral for GC attained after instituting universal CGRA is, to our knowledge, the highest rate reported for unaffected women who have a high-risk family history. 25, [34] [35] [36] An observational study by Bellcross et al 35 that relied on self-reports found that only approximately 14% of women unaffected by breast cancer who met USPSTF guidelines for GC were referred. However, it is unclear from the report whether this represents all women who were referred or only those women who attended a GC appointment. A prospective randomized controlled trial conducted by Kaplan et al 36 used an intervention similar to that of the current study and enrolled patients in primary care practices (academic and at a safety-net hospital). Those investigators found that providing PCPs with the results of risk assessment and recommendations for GC referral significantly increased the rate at which PCPs discussed GC and testing with high-risk patients (odds ratio, 5.99). However, the discussion rate remained relatively low even in the intervention group (21%), and that study was unable to determine the rate of actual referral or attendance at a GC consultation. In the current study, approximately 60% of participants reported in exit interviews that their PCP discussed breast cancer risk with them after the initiation of universal CGRA (data not shown). Attendance at the GC appointment was higher among the referred participants who reported that their PCP discussed breast cancer risk with them (19.6% vs 5.9%), although the rate was still low and the difference did not reach statistical significance due to the small sample size.
We were not able to determine the reasons why individual participants were not referred. However, focus groups held with PCPs after completion of the study suggested that some participants were not referred because the PCP perceived that they were unlikely to attend due to other more pressing medical issues or life challenges or that they did not comprehend the information presented. The data presented herein also suggest that PCPs may have based referral decisions on their perception of financial barriers that patients may encounter. However, these analyses were exploratory, and therefore we cannot draw any conclusions from the data. Ongoing analysis of surveys completed by providers at the conclusion of the study may provide insight regarding this issue.
We found that attendance at a GC session was very low (16% attendance rate among referred women). The study was designed so that PCPs would discuss the CGRA results with the patient and personally recommend GC referral in an effort to improve compliance. 37 Although we did note a trend toward higher attendance among women whose PCP discussed their breast cancer risk during the appointment, this was insufficient to motivate the majority of women to attend a counseling session. Cost could have been perceived as a barrier for this socioeconomically disadvantaged group of women because it is possible that participants were unaware that there was no charge for the counseling. The results of this study are consistent with other reports showing that unaffected women with a high-risk family history utilize cancer genetic services at a very low rate. 25, [34] [35] [36] However, to the best of our knowledge, those studies were unable to clearly isolate the contribution of low rates of PCP referral versus noncompliance among referred women. More work is needed to understand the beliefs and barriers that prevent underserved women from accessing cancer genetic services when such services are recommended by their healthcare provider.
The current feasibility study has several limitations. The small number of both providers and women attending GC limited our ability to identify predictors of adherence to guideline-concordant care. Although the findings have important implications that support efforts to identify high-risk minority women receiving care in FQHCs, they cannot be generalized to populations other than disadvantaged urban minority women. Low health literacy may have affected adherence, but we did not measure that variable or provide uniform education for high-risk women. Future work will need to address this important issue. Finally, we encountered issues with sustainability of the CGRA initiative at the conclusion of the funding period due to the additional workload for clinic staff.
Cancer September 15, 2018 The results of the current study demonstrate that implementing the USPSTF mandate that all women with a family history of breast and/or ovarian cancer are screened for genetic predisposition as part of standard primary health care is feasible in the FQHC setting, and substantially improves the referral of high-risk women for GC. However, uptake of counseling is poor and successful implementation in underserved communities will require additional work to develop effective strategies for increasing the use of cancer genetic services.
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